One of the most compelling findings is the role of the HBV protein HBx in maintaining cccDNA transcriptional activity. HBx interacts with host factors to alter the epigenetic landscape of cccDNA ...
Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...
Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...
1mon
GlobalData on MSNPrecision reports initial outcomes from Hepatitis B trial of PBGENE-HBVPrecision aims to define the optimal dose and number of administrations for the elimination of covalently closed circular DNA (cccDNA), in addition to the inactivation of integrated HBV DNA.
The definition and clinical use of common HBV serological markers are shown in Table 2. HBsAg is the hallmark of HBV infection and is the first serological marker to appear in acute hepatitis B.
“The recent reported clinical experience for PBGENE-HBV focused on viral editing and elimination of replicating cccDNA and integrated HBV DNA in Hepatitis B, an extremely large patient ...
Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains a largely incurable disease impacting more than 290 million people worldwide. All patients with chronic HBV ...
ImmuneMed is developing both its phase 2-ready antiviral drug candidate hzVSF to treat viral diseases including chronic hepatitis B virus (HBV) infection and a line of rapid diagnostic kits to ...
Schematic representation of histone-modifying factor recruitment on cccDNA minichromosomes in relation to viral protein HBx. GA, UNITED STA ...
Dagger; Approximately five copies = 1 IU. ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus. IgM anti-HBc Presence with high index value during acute HBV ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results